Roche has called for a fundamental transformation of global healthcare systems to address the growing burden of non-communicable diseases (NCDs). The company emphasises the need to shift from traditional, hospital-centred care towards sustainable healthcare models that prioritise long-term disease management and prevention.
Existing Healthcare Systems Need Structural Changes
Jorg Rupp, Head of International Operations at Roche, highlighted that healthcare infrastructure developed in the mid-20th century primarily focused on treating acute illnesses. However, the rising prevalence of chronic conditions now requires continuous monitoring, long-term treatment and coordinated patient care. Therefore, healthcare systems must evolve to meet the needs of patients living with chronic diseases while improving treatment outcomes and managing costs.
Healthcare Spending Should Be Viewed as an Investment
Rupp urged governments to consider healthcare spending an investment rather than an expense. He noted that the direct and indirect costs associated with chronic disease treatment could exceed $5 trillion over the next decade. Moreover, untreated chronic diseases contribute to significant productivity losses, affecting economies worldwide. Annual losses could reach up to 15% of global gross domestic product (GDP), highlighting the economic importance of early diagnosis, effective treatment and preventive care.
Emerging Economies Can Adopt New Healthcare Models
According to Rupp, emerging economies have an opportunity to develop more efficient healthcare systems without replicating expensive, hospital-centric models adopted by Western countries. Instead, these nations can prioritise accessible healthcare services, early intervention and integrated approaches to chronic disease management. Such strategies could help governments control healthcare expenditure while expanding access to treatment.
Pharmaceutical Innovation Focuses on Non-Communicable Diseases
Meanwhile, global pharmaceutical research continues to target the growing burden of chronic diseases. Nearly 13,000 new medicines are reportedly in clinical development worldwide, with approximately 75% focused on non-communicable diseases. As reported by firstwordpharma.com, consequently, stronger healthcare infrastructure, improved access to innovative medicines and sustainable funding mechanisms will play an increasingly important role in addressing the global disease burden.